Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Average Rating of “Moderate Buy” from Brokerages

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has been given an average rating of “Moderate Buy” by the eight brokerages that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $43.1429.

Several brokerages recently commented on ZBIO. Jefferies Financial Group reiterated a “buy” rating and set a $48.00 target price on shares of Zenas BioPharma in a report on Tuesday, January 6th. Morgan Stanley lowered shares of Zenas BioPharma from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $37.00 to $19.00 in a research note on Monday, January 5th. Evercore began coverage on shares of Zenas BioPharma in a research report on Wednesday, November 26th. They set an “outperform” rating and a $55.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $44.00 price target on shares of Zenas BioPharma in a report on Tuesday, February 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Monday, December 29th.

Zenas BioPharma Trading Down 0.0%

NASDAQ:ZBIO opened at $26.35 on Friday. The business’s 50-day moving average is $25.35 and its two-hundred day moving average is $26.40. The firm has a market capitalization of $1.41 billion, a PE ratio of -3.73 and a beta of -1.50. Zenas BioPharma has a 12 month low of $6.11 and a 12 month high of $44.60. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.66 and a quick ratio of 5.66.

Insider Transactions at Zenas BioPharma

In other Zenas BioPharma news, Director Hongbo Lu bought 25,985 shares of Zenas BioPharma stock in a transaction dated Wednesday, February 11th. The stock was bought at an average cost of $22.50 per share, for a total transaction of $584,662.50. Following the purchase, the director owned 347,968 shares in the company, valued at $7,829,280. This represents a 8.07% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Patricia L. Allen purchased 4,160 shares of the firm’s stock in a transaction dated Friday, February 13th. The shares were bought at an average cost of $26.36 per share, with a total value of $109,657.60. Following the transaction, the director directly owned 19,860 shares of the company’s stock, valued at approximately $523,509.60. This represents a 26.50% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have acquired 202,845 shares of company stock valued at $3,747,185. 16.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. SR One Capital Management LP increased its position in shares of Zenas BioPharma by 2.6% in the 4th quarter. SR One Capital Management LP now owns 5,037,854 shares of the company’s stock worth $182,924,000 after purchasing an additional 126,315 shares during the last quarter. NEA Management Company LLC grew its stake in Zenas BioPharma by 28.9% in the fourth quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock worth $127,928,000 after purchasing an additional 789,500 shares in the last quarter. Federated Hermes Inc. increased its holdings in Zenas BioPharma by 45.9% in the fourth quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock valued at $98,603,000 after buying an additional 853,740 shares during the last quarter. Vanguard Group Inc. increased its holdings in Zenas BioPharma by 25.0% in the fourth quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock valued at $52,761,000 after buying an additional 290,307 shares during the last quarter. Finally, Polar Capital Holdings Plc acquired a new stake in Zenas BioPharma during the fourth quarter valued at approximately $38,402,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.